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802-1 Elaboration and Validation of a Prognostic 
Classification for Severe Chronic Heart Failure: Data 
From EPICAL and RALES Studies 
Francois Alia, Serge Brianqon, Faiez Zannad, INSERM-CHU, Nancy, France. 
The clinical management of severe congestive heart failure (CHF) should be graded 
according to prognosis in each individual patient. The aim of our study was to elaborate 
and validate a survival prognostic score for patients with severe CHF, based on readily 
available clinical variables, 
Methods: The EPICAL database provided the score elaboration sample (observational, 
community-based study - 417 patients, NYHA Ill/IV, LVEF <30%, 5 years follow-up) ; 
RALES provided the independent validation sample (clinical trial, spironolactone vs. pla- 
cebo - sub-sample of 261 patients, NYHA Ill/IV, LVEF <35%, 2 years follow-up). Baseline 
variables were tested in Cox multivariate models. The score was defined in the form of 
linear combinations of the variables included in the model. 
Results: Two-years survival rates were 61% in both groups. Five-year survival was 36% 
in EPICAL, Seven factors were independently associated with survival rate in the EPI- 
CAL sample. From theses variables and respective coefficients, the prognostic score 
may be calculated for each patient as follows: Score = 4 (age greater than (gt) 60 years) 
+ 3 (duration of causa~ disease gt 1 year) + 2 (prior heart failure decompensation) + 2 
(serum sodium It 138 pmol/I) + 3 (co-morbidity) + 6 (renal impairment) + 3 (furosemide 
dose gt 120rag/d). Scores ranged from 0 to 23 ; the higher the score the poorer the sur- 
vival. With best cutpoints, we have constituted a three classes final score: It 7 (class I), 
between 7 and 11 (class II), gt 11 (class III). Two-years survival rates were 87% for class 
I ,  66% for class II and 40% for class Ill. Five-year survival-rates were 67% for class I, 
38% for class II and 13% for class Ill. 
The application of this score in the validation sample, showed no differences between 
predicted and observed survival: two-years survival-rates were 86% for class I, 59% for 
class II and 35% for class III (p vs. EPICAL NS). 
Conclusion: A simple validated score is able to discriminate among advanced CHF 
patients with low and high risk of death. It may help to identify patients who should be 
referred for specialist advice or intensive therapy and to manage transplantation waiting 
lists. It may also provide a useful tool for clinical trials design and analysis. 
9:30 a.m. 
802-2 A H is tory  of Prior Myocardial Infarction Was 
Independently Predictive of Mortality but Not of 
Recurrent Myocardial Infarction or Heart Failure 
Hospitalization in 5477 Patients With Acute Myocardial 
Infarction Complicated by Cardiac Failure 
Ronnie Willenheimer, Klas Gr~nsbo, Staven Snapinn, Andrew Coats, for the OPTIMAAL 
study group, University Hospital MAS, Malmd, Sweden. 
Background: In a large cohort of patients with acute myocardial infarction (AMI) compli- 
cated by cardiac failure, we examined any relationship between a history of pdor AMI 
and future morbidity and mortality. 
Methods: In 5477 patients with AMI and clinical signs of heart failure (HF) and/or systolic 
left ventricular dysfunction and/or anterior Q-wave AMI, a history of AMI and 50 other 
variables comprising demographics, patient history, physical examination, laboratory val- 
ues and medication were assessed at baseline. Patients were followed-up for a mean of 
2.5 years. The value of a history of prior AMI to predict recurrent AMI, HF hospitalization, 
cardiac death and total mortality was tested in uni- and multivariate analysis using a Cox 
regression model. 
Results: During follow-up there were 657 recurrent AMIs, 625 HF hospitalizations, 403 
cardiac deaths and 844 deaths. In univadata analysis a history of prior AMI was signifi- 
cantly predictive of recurrent AMI (HR 1.765, 95 % CI 1.457-2.138, P<0.00Ol), HF hospi- 
talization (HR 1.695, 95 % CI 1.401 -2.051, P<0.0001 ), cardiac death (HR 2.091,95 % CI 
1.654-2.643, P<0.0001) and all cause mortality (HR 1.904, 95 % CI 1.620-2.237, 
P<0.0001). 
In multivariate analysis, however, a history of AMI was not independently predictive of 
recurrent AMI or HF hospitalization, but of cardiac death (HR 1.797, 95 % CI 1.418- 
2.278, P<0.0001) and all cause morlality (HR 1,403, 95 % CI 1.179-1.669, P=0.0001). 
Variables independently predictive of recurrent AMI were age (HR 1.025/year, 
P<0.0001), inclusion based on Q-wave AMI (HR 0.738, P=0.0003), prior Aspirin use (HR 
1.617, P<0.0001 ) and country of residence. 
Variables independently predictive of HF hospitalization were age (HR 1.043/ysar, 
P<0.0001), pulmonary congestion at X-ray (HR 1.573, P<0.0001), history of diabetes 
(HR 1.655, P<0+0001), prior diuretic use (HR 1.562, P<0.0001), pulse rate (HR 1,016/ 
beat/rain, P<0.0001), serum urea (HR 1.067, P<0.0001), smoking (HR 1.228, P=0.0003), 
and country of residence. 
Conclusion: fn a high risk post AMI population a history of AMI was independently predic- 
tive of cardiac and all cause mortality, but not of recurrent AMI or HF hospitalization, in 
this multivariate model. 
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802-3 Impact of Combining Fatal and Nonfatal Endpoints in 
Heart Failure Trlala 
Hicham Skali, Scott D. Solomon, Jacobus Lubsan, Marc A. Pfeffer, Brigham and 
Women's Hospital, Boston, Massachusetts, SOCAR Research SA, Nyon, Switzerland. 
Background: In randomized clinical trials (RCT), sample size is often estimated based 
on a presumed endpoint event rate. Frequently, composite endpoints are constructed to 
have more events in the population and hence reduce that sample. 
Aim: To test the assumption that using a composite endpoint of heart failure (HF) hospi- 
talization (hosp) or death results in a consistent increase in event rate across HF RCTs. 
Methods: HF trials were selected if they enrolled more than 1000 patients for a mean fol- 
low-up of at least 9 months and if the endpoints evaluated included mortality and a com- 
posite endpoint of death or HF hosp. Average duration of the placebo arm follow-up was 
derived from the mean duration of follow-up in both arms and mortality odds ratio. Pla- 
cebo event rates per 100 patient-years (pt-yrs) of follow-up for mortality and the compos- 
ite endpoint were estimated. The Increment was defined as the difference in event rates 
between the composite endpoint and mortality. 
Results: Eight major RCT met the entry criteria. Events rates per 100 pt-yrs of follow-up 
ranged from 5.5 to 43.7 for death and from 9.1 to 49.7 for the composite endpoint. The 
increment rate in each trial ranged from 3.5 to 26.6 events per 100 pt-yrs of follow-up. 
The increment was not correlated with mortality rate (r=0.11, p=0.79). 
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Conclusion: Although combining HF hosp with death increases event rates, the abso- 
lute increment varies widely unrelated to disease severity. In HF RCTs, sample size esti- 
mation based on this composite endpoint is unreliable. 
10:00 a.m. 
802-4 The Impact of Gender on Prognosis in Patients With 
Advanced Heart Failure 
Jalal K, GhalL Heidi Krause-Stainrauf, Kirkwood F. Adams, Jr,, Steven Goldman, Steven 
S. Khan, Mary A. Peberdy, Yves D. Rosenberg, Clyde W. Yancy, Jr,, James B. Young, 
JoAnn Lindenfeld, Cardiac Centers of Louisiana, Shreveport, Louisiana. 
We examined the effect of gender on prognosis in the Beta Blocker Evaluation of 
Survival Trial (BEST), which randomized 2115 men and 593 women with heart failure 
(NYHA class III or IV with LVEF _< 35 %) to bucindoloI or placebo. Complete data were 
available on 579 women and 2049 men. Women were younger (mean age 58 vs 61 
years), included more blacks (30% vs 21%), less CAD (36%vs 62%), higher LVEF (25% 
vs 23%), and similar number of diabetics (36% vs 35%). A multivariate analysis, using 
Cox proportional hazard regression, was performed to assess the predictive value of 
several clinical and laboratory variables on prognosis. Conclusion In patients with 
advanced heart failure and impaired LVEF, female gender plays a protective role and is 
an independent predictor of survival with men having 32% increase in risk of death after 
adjusting for major variables known to impact prognosis. This finding is relevant in 
designing clinical trials and assessing the potential rote of new management strategies 
on survival in patients with advanced heart failure. 
N = 2628 Events = 838 
Covariata HR 98% CI p-value 
CAD (CAD vs non CAD) 1.46 1.25-1.71 0.0001 
SBP (mm Hg) 0.99 0.99-0.99 0.0001 
CTR 1.03 1.02-1.04 0.0001 
Age (year) 1.02 1.01-1.02 0.0001 
LVEF (<.20 vs >.20) 0.78 0.67-0.91 0.0010 
NYHA (iV vs III) 1.42 1.15-1.75 0.0010 
Diabetes Mellitus 1.25 1.08-1.45 0.0023 
Gender (male vs female) 1.32 1.09-1.59 0.0040 
Race (black vs nonbleck) 1.24 1,05-1.47 0.0115 
